Cellceutix: Dermatology Overview (Cellceutix) - Jul 16, 2016 - "Prurisol met the primary endpoint (a 2-point IGA reduction) in 35% of all patients who received a dose of 200mg per day"; "Among patients with the severest form of psoriasis, those having a baseline IGA score of 3 (“moderate”), the primary endpoint was met in 46% of patients who received 200mg per day. This data was derived from analyses of all patients"; "Patients who received any dose of Prurisol, regardless of the treatment arm, had a 1-point IGA improvement"; "Patients reported improved general skin condition, e.g., skin felt moist and smoother"; "Prurisol was well-tolerated—just one Serious Adverse Event (SAE) occurred and it was in the 50mg dose group"; "PK results showed a dose-dependent increase in exposure and maximum plasma concentration of the drug. The elimination half-life was similar in each of the three dosing levels (50mg, 100mg, 200mg), with an average of 1.3 hours. The clearance of the drug was also similar across dosing levels, with an average..."
P2 data • Psoriasis
|